L. Rosen

发表

Strategies to Address Challenges in Neuroscience Drug Discovery and Development

C. Davies, P. O’Donnell, R. Alexander, 2019, The international journal of neuropsychopharmacology.

Lack of Effect of Aprepitant on Hydrodolasetron Pharmacokinetics in CYP2D6 Extensive and Poor Metabolizers

P. Lupinacci, T. Rushmore, E. Pequignot, 2006, Journal of clinical pharmacology.

Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics

J. Mullen, P. Daga, D. Bender, 2018, Clinical pharmacology in drug development.

Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers

D. Buhl, P. O’Donnell, J. V. van Gerven, 2022, Translational Psychiatry.

Safety, pharmacokinetics and pharmacodynamics of TAK‐418, a novel inhibitor of the epigenetic modulator lysine‐specific demethylase 1A

J. Wendland, M. Bednar, Saurabh Gupta, 2021, British journal of clinical pharmacology.

AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease.

S. Haeberlein, L. Ereshefsky, S. Eketjäll, 2016, Journal of Alzheimer's disease : JAD.

Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man

Steven V. Fox, J. Renger, P. Coleman, 2016, Scientific Reports.

Orexin 2 receptor‐selective agonist danavorexton (TAK‐925) promotes wakefulness in non‐human primates and healthy individuals

Yaming Hang, H. Faessel, H. Yukitake, 2023, Journal of sleep research.

Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.

C. Lines, J. Chodakewitz, Junshui Ma, 2013, Sleep.

O4-03-02 The gamma secretase inhibitor MK-0752 acutely and significantly reduces CSF Abeta40 concentrations in humans

L. Ereshefsky, A. Plump, K. Gottesdiener, 2006, Alzheimer's & Dementia.

Results of a phase 1, 4-period crossover, placebo-controlled, randomized, single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-925, a novel orexin 2 receptor agonist, in sleep-deprived healthy adults, utilizing modafinil as an active comparator

H. Faessel, R. Alexander, L. Rosen, 2019 .

Safety, pharmacokinetics and quantitative EEG modulation of TAK‐071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects

D. Buhl, F. Mamashli, A. Simen, 2021, British journal of clinical pharmacology.

Early‐stage comparative effectiveness: Randomized controlled trial with histamine inverse agonist MK‐7288 in excessive daytime sleepiness patients

C. Lines, J. Renger, G. Kay, 2013, Journal of clinical pharmacology.

A novel multivalent Abeta peptide vaccine with preclinical evidence of a central immune response that generates antisera recognizing a wide range of Abeta peptide species

J. Renger, A. McCampbell, M. Citron, 2010, Alzheimer's & Dementia.

A Phase 1 single ascending dose study of a novel orexin 2 receptor agonist, TAK-925, in healthy volunteers (HV) and subjects with narcolepsy type 1 (NT1) to assess safety, tolerability, pharmacokinetics, and pharmacodynamic outcomes

S. Touno, H. Faessel, R. Alexander, 2019 .

Equivalent Dynamic Human Brain NK1‐Receptor Occupancy Following Single‐Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging

G. Bormans, K. Van Laere, R. Hargreaves, 2012, Clinical pharmacology and therapeutics.

Early‐stage comparative effectiveness: Randomized controlled trial with histamine inverse agonist MK‐7288 in excessive daytime sleepiness patients

C. Lines, J. Renger, G. Kay, 2013, Journal of clinical pharmacology.